Advances in biomarkers for the early diagnosis of prostate cancer
- VernacularTitle:分子标志物在前列腺癌早期诊断中的进展
- Author:
Cao DA-LONG
1
;
Yao XU-DONG
Author Information
1. 复旦大学附属肿瘤医院
- Keywords:
Prostate cancer;
biomarker;
early diagnosis
- From:Chinese Journal of Cancer
2010;29(2):245-249
- CountryChina
- Language:Chinese
-
Abstract:
More and more studies have revealed that the level of serum PSA has no ability to guide the early diagnosis of prostate cancer(Pca).For example, negative prostate biopsies are as high as 70%-80% for patients with serum prostate specific antigen(PSA)ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of Pca, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives.HPCI,PCA3,TMPRSS2:ETS,GSTPl,AMACR,GOLPH2,EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the early diagnosis and the prognostic monitoring of patients with Pca.
